- There were around 11,900 new cases of kidney cancer in the UK in 2013, that’s 33 cases diagnosed every day.
- Kidney cancer is the seventh most common cancer in the UK (2013).
- Kidney cancer accounts for 3% of all new cases in the UK (2013).
- In males in the UK, kidney cancer is the fifth most common cancer, with around 7,500 cases diagnosed in 2013.
- In females in the UK, kidney cancer is the 10th most common cancer, with around 4,400 cases diagnosed in 2013.
- Half (50%) of kidney cancer cases in the UK each year are diagnosed in people aged 70 and over (2011-2013).
- Since the late 1970s, kidney cancer incidence rates have more than doubled (166% increase) in Great Britain. The increase is larger in females (175% increase), than in males (149% increase).
- Over the last decade, kidney cancer incidence rates have increased by almost two-fifths (38%) in the UK. The increase is larger in females (40%), than in males (35%).
- Most kidney cancer cases are diagnosed at an early stage.
- Kidney cancer in England is more common in people living in the most deprived areas.
- Most kidney cancers occur in the kidney itself.
- In Europe, more than 115,000 new cases of kidney cancer were estimated to have been diagnosed in 2012. The UK incidence rate is 19th lowest in Europe for males and 17th highest for females.
- Worldwide, around 338,000 people were diagnosed with kidney cancer in 2012, with incidence rates varying across the world.
- 1 in 52 men and 1 in 87 women will be diagnosed with kidney cancer during their lifetime.
Kidney cancer statistics
New cases of kidney cancer, 2013, UK
Deaths from kidney cancer, 2014, UK
Survive kidney cancer for 10 or more years, 2010-11, England and Wales
Preventable cases of kidney cancer, UK
- There were around 4,400 kidney cancer deaths in the UK in 2014, that’s 12 deaths every day.
- Kidney cancer is the 13th most common cause of cancer death in the UK (2014).
- Kidney cancer accounts for 3% of all cancer deaths in the UK (2014).
- In males in the UK, kidney cancer is the 10th most common cause of cancer death, with around 2,800 deaths in 2014.
- In females in the UK, kidney cancer is the 14th most common cause of cancer death, with around 1,600 deaths in 2014.
- Three-quarters of deaths from kidney cancer are in people aged 65 and over.
- Since the early-1970s, kidney cancer death rates in the UK have increased by half.
- Kidney cancer deaths in England are more common in people living in the most deprived areas.
- In Europe, around 49,000 people were estimated to have died from kidney cancer in 2012. The UK mortality rate is 20th lowest in Europe for males and 12th highest for females.
- Worldwide, more than 143,000 people were estimated to have died from kidney cancer in 2012, with mortality rates varying across the world.
- Half (50%) of people diagnosed with kidney cancer in England and Wales survive their disease for ten years or more (2010-11).
- Almost 6 in 10 (56%) people diagnosed with kidney cancer in England and Wales survive their disease for five years or more (2010-11).
- More than 7 in 10 (72%) people diagnosed with kidney cancer in England and Wales survive their disease for one year or more (2010-11).
- Kidney cancer survival is higher in men than women at one- and five-years but similar at ten-years (2010-2011).
- Kidney cancer survival in England is highest for people diagnosed aged under 50 years old (2009-2013).
- Around three-quarters of people in England diagnosed with Kidney cancer aged 15-49 survive their disease for five years or more, compared with more than a third of people diagnosed aged 80 and over (2009-2013).
- Kidney cancer survival is improving and has increased in the last 40 years in the UK.
- In the 1970s, almost a quarter of people diagnosed with kidney cancer survived their disease beyond ten years, now it's half.
- When diagnosed at its earliest stage, more than 8 in 10 people with kidney cancer will survive their disease for five years or more, compared with less than 1 in 10 people when at the latest stage.
- 42% (47% in males and 34% in females) of kidney cancer cases each year in the UK are linked to major lifestyle and other risk factors.
- A person’s risk of developing kidney cancer depends on many factors, including age,genetics, and exposure to risk factors (including some potentially avoidable lifestyle factors).
- An estimated 42% of kidney cancers in the UK are linked to lifestyle factors including smoking (24%) and overweight and obesity (24%).
- Ionising radiation, certain occupational exposures, and certain medicines cause kidney cancer.
- Certain medical conditions and inadequate physical activity may relate to higher kidney cancer risk.
- GP referral (not ‘two week wait’) is the most common route to diagnosis of kidney cancer.
- GP referral is the route with the highest proportion of cases diagnosed at an early stage, for kidney cancer.
- ‘Two-week wait’ standards are met by all countries, ‘31-day wait’ and ‘62-day wait’ are not met by any country for urological cancers.
- Almost 6 in 10 kidney cancer patients receive major surgical resection as part of their cancer treatment.
- More than 8 in 10 patients had a ‘very good’ or ‘excellent’ patient experience.
- Around 7 in 10 patients are given the name of their Clinical Nurse Specialist.
The latest statistics available for kidney cancer in the UK are; incidence 2013, mortality 2014 and survival 2010-2011 (all ages combined) and 2009-2013 (by age).
European Age-Standardised Rates were calculated using the 1976 European Standard Population (ESP) unless otherwise stated as calculated with ESP2013. ASRs calculated with ESP2013 are not comparable with ASRs calculated with ESP1976.
Lifetime risk estimates were calculated using incidence, mortality, population and all-cause mortality data for 2012.
Survival statistics give an overall picture of survival and (unless otherwise stated) include all adults (15-99) diagnosed, at all ages,
Stage at diagnosis data is not yet routinely available for the UK due to inconsistencies in the collecting and recording of staging data in the past.
Risk factor evidence is for renal cell carcinoma (RCC) unless otherwise specified.
Routes to diagnosis statistics were calculated from cases of cancer registered in England which were diagnosed in 2012-2013. Staging proportions only include patients with a known stage (cases with an unknown stage at diagnosis are not included in the denominator).
Cancer waiting times statistics are for patients who entered the health care system within financial year 2014-15. Kidney cancer is part of the group 'Urological cancer' for cancer waiting times data. Codes vary per country but broadly include: penis, prostate, testis, other and unspecified male genital organs, kidney, renal pelvis, ureter, bladder, other and unspecified urinary organs, secondary cancers of kidney, renal pelvis, bladder and other unspecified urinary organs.
Cancer surgical resection rates data is for patients diagnosed in England between 2006 and 2010.
Patient Experience data is for adult patients in England with a primary diagnosis of cancer, who were in active treatment between September and November 2013 and who completed a survey in 2014.
Deprivation gradient statistics were calculated using incidence data for three time periods: 1996-2000, 2001-2005 and 2006-2010 and for mortality for two time periods: 2002-2006 and 2007-2011. The 1997-2001 mortality data were only used for the all cancers combined group as this time period includes the change in coding from ICD-9 to ICD-10. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN report.
You are welcome to reuse this Cancer Research UK statistics content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:
Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.